BoMRA has partnered with Quntrol Laboratories, India, through an MoU to Strengthen Medicine Regulation.
The MoU was signed on the 15th of October 2024, in India, where BoMRA CEO, Dr. Seima Dijeng, is attending the 19th International Conference for Drug Regulatory Authorities. At the signing ceremony, Dr Dijeng emphasized that BoMRA aims to facilitate access to safe, high-quality, and effective medicines by establishing Pre-Shipment Inspection (PSI) and testing for medicines imported into Botswana. He stated that this initiative “will provide third-party, unbiased validation of the quality, safety, and efficacy of medicines, rather than relying solely on the manufacturer’s quality assessments. This will help reduce the circulation of substandard medical products in Botswana.”
Mrs. Riddhi Javeri, Director of Quntrol Laboratories Ltd, expressed her gratitude for being appointed as the pre-shipment inspection agency. She noted, “Quntrol Laboratories has been offering this service for more than six years. We currently provide it to the Government of Mozambique through the Ministry of Health, the National Agency for Food and Drug Administration and Control of Nigeria, and the Medicines Control Agency (MCA) of Gambia.